← boardnext 2026-12next 2027-01next 2028-05-31
PRAX
Praxis Precision Medicinesdistress 3/10 · well-funded / low risk$311.200%today-13% from 52w high
Neurology 1
Lead: focal onset seizures
Revenue
pre-revenue
Liquidity
$1448M
Runway
5.1 yrs
Shares 1y
+33%
Price & events
+2.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.3%
1D
+1.0%
1W
+1.9%
1M
-5.6%
3M
-0.2%
6M
+445.1%
1Y
+434.6%
2Y
+26.6%
5Y
-61.7%
All
Overview
- Market Cap
- $8.68B
- Volume
- 61.87K
- 52 Week Range
- $37.70 – $357
- Total Shares
- 27.88M
- Float Shares
- 24.04M
- Short %
- 14.34%
- % Held by Insiders
- 0.28%
- % Held by Institutions
- 116.72%
- RVOL
- 0.12x
- Beta
- 2.76
Pipeline stages · 4 programs
1.0mg/kg/day PRAX-562, 1.5mg/kg/day PRAX-562
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
40 mg/day vormatrogine for 12 weeks, 30 mg/day vormatrogine for 12 weeks, 20 mg/day vormat
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
vormatrogine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
PRAX-222 - Initial Dose, PRAX-222 - Initial Ascending Doses, PRAX-222 - Optional Ascending Doses, PRAX-222 - Fixed Doses
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 5 trials · 3 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12 Estimated 50% readout ~2027-02-14 | Phase 3 | 1.0mg/kg/day PRAX-562, 1.5mg/kg/day PRAX-562 | Developmental and Epileptic Encephalopathy 1 | — | recruiting |
| 2027-01 Estimated 50% readout ~2027-03-17 | Phase 3 | 40 mg/day vormatrogine for 12 weeks, 30 mg/day vormatrogine for 12 weeks, 20 mg/day vormat | Focal Epilepsy | — | recruiting |
| 2028-05-31 Estimated 50% readout ~2028-08-14 | Phase 3 | vormatrogine | Epilepsy, Tonic-Clonic, Focal Seizure, Primary Generalized Seizure | — | enrolling by invitation |
| 2025-08 | Phase 1/2 | PRAX-222 - Initial Dose, PRAX-222 - Initial Ascending Doses, PRAX-222 - Optional Ascending Doses, PRAX-222 - Fixed Doses | SCN2A-DEE, Epilepsy | 60 | recruiting |
| 2025-05-30 | Phase 1 | PRAX-628 | Healthy | 16 | not yet recruiting |
Upcoming readouts & decisions · our signals
1 upcoming event has our read — the sell-the-news timing call plus an experimental clinical estimate. Go Pro to see them.
Catalyst news & presentations · 21
- January 29, 2027Confirmed 100%PDUFAPDUFAulixacaltamide HCl · PDUFA target action date setSEC 8-K
- second half of 2026Guided 55%enrollment completesecondaryvormatrigine · POWER2 study completion on trackSEC 8-K
- December 27, 2026Confirmed 100%PDUFAPDUFArelutrigine · updated PDUFA target action dateSEC 8-K
- September 27, 2026Confirmed 100%PDUFAPDUFArelutrigine · PDUFA target action date for relutrigine NDASEC 8-K
- 2026-08-10earningsEarningsEarnings releaseyahoo
- 2026-07-07partnershipulixacaltamide · Research collaboration for iontophoretic transdermal patch for essential tremor.SEC 8-K
- first half of 2026trial initiationsecondaryvormatrigine · POWER3 monotherapy study startSEC 8-K
- first half of 2026readoutPhase 3elsunersen · Topline results from EMBRAVE Study Part ASEC 8-K
- 2026-06-29pdufa extensionrelutrigine · FDA extended review period by 3 months due to major amendment; no safety/manufacturing concernsSEC 8-K
- April 14, 2026filing acceptanceFiled (NDA/BLA)ulixacaltamide HCl · FDA accepted for review New Drug ApplicationSEC 8-K
- early 2026regulatory submissionFiled (NDA/BLA)ulixacaltamide · Plan to submit NDA to FDASEC 8-K
- early 2026regulatory submissionFiled (NDA/BLA)relutrigine · NDA filing for relutrigine in SCN2A and SCN8A DEEsSEC 8-K
- 2026-01-06partnershipUnderwriting agreement with Piper Sandler, TD Securities, Guggenheim for public offering of common stock.SEC 8-K
- December 2025conferencedata presentationsecondaryvormatrigine · Late-breaker abstract submission for American Epilepsy Society Annual MeetingSEC 8-K
- 2025-12-11fda agreementrelutrigine · FDA confirmed plan to file NDA for relutrigine in SCN2A and SCN8A DEEs.SEC 8-K
- 2025-12-09fda agreementelsunersen · FDA agreed to convert EMBRAVE3 into a single-arm study with 30 patients and primary endpoint of change from baseline in countable motor seizures.SEC 8-K
- 2025-12-04fda agreementulixacaltamide · Pre-NDA meeting alignment on NDA contentSEC 8-K
- 2025-12-04enrollment completesecondaryvormatrigine · Completed recruitment for POWER1 studySEC 8-K
- 2025-12-04readoutPhase 3relutrigine · Positive topline results from EMBOLD studySEC 8-K
- August 31, 2025conferencedata presentationsecondaryvormatrigine · Presenting additional data from RADIANT study at 36th International Epilepsy CongressSEC 8-K
- July 17, 2025trial initiationsecondaryrelutrigine · Initiated EMERALD study evaluating relutrigine in patients across all DEEs.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $610 (+96% upside) · 19 analysts
- 2026-07-13Goldman SachsBuy
- 2026-06-29NeedhamBuy
- 2026-06-18RBC CapitalOutperform
- 2026-06-02BairdOutperform
- 2026-06-02BTIGBuy
- 2026-06-02Deutsche BankBuy
Competitors — focal onset seizures
Recent news
- 2026-07-22Praxis Precision Medicines: Priced For Half Of What I Think It's Worth (NASDAQ:PRAX) - Seeking Alpha
- 2026-07-22Praxis Precision Medicines (PRAX) Bank of America Global Healthcare Conference 2026 summary - Quartr
- 2026-07-21Former Prax worker bounces back from redundancy with new family venture - Grimsby Live
- 2026-07-20Praxis Precision Medicines (PRAX) Could Be 49% Undervalued As Patch Deal Expands Ulixacaltamide Reach - simplywall.st
- 2026-07-16Kaleidoscope Festival mixes science and art at PRAx - The Daily Barometer
- 2026-07-16Should Praxis–Remagine Transdermal Patch Collaboration and FDA Review Extension Reshape PRAX Pipeline Expectations? - simplywall.st
- 2026-07-15ISU Summer prax - MyWabashValley.com
- 2026-07-15Praxis Precision Medicines (PRAX) Enters Into Licensing and Research Collaboration With Remagine Labs - Yahoo Finance
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.